

Ref: STEX/RPT/2023-24

Dated 30.05.2023

BSE Limited
Floor 25, P J Towers
Dalal Street
Mumbai-400001

National Stock Exchange of India Ltd
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Code-531146

NSE Code: MEDICAMEQ

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir,

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith details of related party transactions on consolidated basis for the half year ended on March 31, 2023.

You are requested to take the same on record.

Thanking You

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary

Encl: As Above.

General information about company	
Name of The Company	Medicamen Biotech Limited
BSE Scrip Code	531146
NSE Symbol	MEDICAMEQ
MSE Symbol	NA
Date of Start of Financial Year	01-04-2022
Date of End of Financial Year	31-03-2023
Reporting Period	Second half yearly
Date of Start of Reporting Period	01-10-2022
Date of End of Reporting Period	31-03-2023
Level of rounding to be used in disclosing related party transactions	Lakhs
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes

(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

[Home](#)[Validate](#)**Related party transactions**

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr No.	Details of the party (listed entity /subsidiary) entering into the	Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Notes	
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured		Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
	Add	Delete																		
1	Medicamen Biotech Limited	Shivalik Rasayan Limited	Holding Company	Sale of goods or services			Approved	1.48	0.00	0.00										
2	Medicamen Biotech Limited	Shivalik Rasayan Limited	Holding Company	Any other transaction	Rent received		Approved	7.08	0.00	0.00										
3	Medicamen Biotech Limited	Shivalik Rasayan Limited	Holding Company	Any other transaction	Reimbursement of expenses		Approved	45.28	0.00	0.00										
4	Medicamen Biotech Limited	Shivalik Rasayan Limited	Holding Company	Any other transaction	Purchase of goods or services		Approved	306.63	0.00	0.00										
5	Medicamen Biotech Limited	Kanchan sharma	Related person to the Director	Any other transaction	Rent Paid		Approved	2.36	0.00	0.00										
6	Medicamen Biotech Limited	Growel Remedies Ltd	Entities with joint control or significant influence over	Any other transaction	Purchase of goods or services		Approved	236.00	0.00	0.00										
7	Medicamen Biotech Limited	Medicamen Life Sciences Private Limited	Subsidiary Company	Any other transaction	Reimbursement of expenses		Approved	18.04	0.00	0.00										
8	Medicamen Biotech Limited	Chem Pharma Pvt Ltd	Entities with joint control or significant influence over	Any other transaction	Professional Charges Paid		Approved	14.16	0.00	0.00										
9	Medicamen Biotech Limited	Shivalik Rasayan Limited	Holding Company	Any other transaction	Payable		Approved	0.00	391.86	273.04										
10	Medicamen Biotech Limited	Opal Pharmaceuticals Pty Ltd.	wholly owned subsidiary	Any other transaction	Receivable		Approved	0.00	78.66	78.66										
11	Medicamen Biotech Limited	Medicamen Life Sciences Private Limited	Subsidiary Company	Any other transaction	Receivable		Approved	0.00	0.00	33.88										
12	Medicamen Biotech Limited	Rajesh Madan	KMP (CEO)	Remuneration			Approved	29.92	0.00	0.00										
13	Medicamen Biotech Limited	Pratap Singh Rawat	KMP (CFO)	Remuneration			Approved	7.34	0.00	0.00										
14	Medicamen Biotech Limited	Parul Choudhary	KMP (CS)	Remuneration			Approved	3.43	0.00	0.00										
15	Medicamen Biotech Limited	Ayan Sharma	Related person to the Director	Any other transaction	Rent Paid		Approved	1.36	0.00	0.00										
Total value of transaction during the reporting period								673.08												